Posted by Michael Wonder on 28 Mar 2022
Dupixent (dupilumab injection) now approved in Canada for the treatment of severe asthma in children aged six to 11 years with type 2 inflammation
28 March 2022 - This is the sixth indication for Dupixent in Canada, its second in asthma, and its second in children aged six to 11 years.
Today Sanofi Canada announced the expanded approval of Dupixent (dupilumab injection) as an add-on maintenance treatment in patients aged six to 11 years with severe asthma with a type 2 / eosinophilic phenotype or oral corticosteroid-dependent asthma.
The approval is based on the pivotal VOYAGE phase 3 trial which enrolled 408 children aged six to 11 years with uncontrolled moderate to severe asthma.
